NetworkNewsBreaks Archive - Page 402 of 2230

MondaySep 30, 2024 1:35 pm

NetworkNewsBreaks – DoubleDown Interactive Co. Ltd. (NASDAQ: DDI) Extends Partnership with American Cancer Society to Support ‘Impactful Work’

DoubleDown Interactive (NASDAQ: DDI), a leading developer and publisher of digital games on mobile and web-based platforms, today announced plans to donate $10,000 to the American Cancer Society during Breast Cancer Awareness Month. According to the announcement, DoubleDown Casino will host the Penny’s Stride for the Cure play-to-enter giveaway on October 5-6, 2024. The event will offer players the opportunity to engage with and show support for the charitable donation and learn more about the importance of the organization’s annual Making Strides Against Breast Cancer walks. “DoubleDown Interactive is proud to partner with the American Cancer Society for the fourth…

MondaySep 30, 2024 1:22 pm

NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Filing of Three Patents Covering Combination Therapies for AD, PD

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), has filed three new patents. According to the announcement, the patents cover combination therapies involving its lead compound, buntanetap, combined with Trulicity(R)(dulaglutide) and Viagra(R)(sildenafil), as well as a combination of all three. The company noted buntanetap inhibits the production of neurotoxic proteins and has been shown to improve cognition in early AD patients and halt cognitive decline in PD patients. “Our early data suggests a strong synergistic effect from combining these drugs, resulting in significant cognitive enhancement,” said Annovis…

MondaySep 30, 2024 11:40 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Series of Direct Offerings, Concurrent Private Placements Totaling $7.3M

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has entered into a securities purchase agreement. The company entered the agreement, which calls for the issue and sale of 742,626 shares of common stock (or prefunded warrants in lieu thereof) with a healthcare-focused institutional investor. The company also noted it had entered into additional agreement and placements with current investors as well as directors and officers of Clene. Gross proceeds from the transactions will total an estimated $7.3 million, before standard deductions and fees. Canaccord Genuity is acting…

MondaySep 30, 2024 11:40 am

NetworkNewsBreaks – WAGMI Miami, LIF3.com Partner for Upcoming 2025 Conference

WAGMI Miami, the flagship event for blockchain and Web3 innovators, today announced LIF3.com, a complete, omni-channel DeFi ecosystem and a leader in decentralized finance, as a Platinum Sponsor for the upcoming conference scheduled for January 21-24, 2025. The partnership is expected to play a crucial role in helping support the advancement of decentralized finance’s future through innovation and collaboration. The announcement noted that with LIFE.com now onboard as a sponsor, the 2025 WAGMI Miami event is poised to be the most impactful and exciting edition yet. “Partnering with LIF3.com is a milestone for WAGMI Miami,” commented Moe Levin, Founder of…

MondaySep 30, 2024 11:25 am

NetworkNewsBreaks – Snap Inc. (NYSE: SNAP) Unveils New Spectacles: A Potential Financial Game-Changer

Snap (NYSE: SNAP), known for its popular social media platform Snapchat, has recently unveiled a new version of its Spectacles. This move is generating buzz for its potential to transform an innovative product into a financial win for the company. Snap has often been at the forefront of blending hardware and software, but turning these innovations into profit has been a challenge. The latest Spectacles could be a game-changer, leveraging Snap’s unique position in the market. The company’s ability to create products that stand out, both in terms of hardware and software, is noteworthy. Snap’s operating system is designed to…

MondaySep 30, 2024 10:51 am

NetworkNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) CEO Joins Expert Panel at Long COVID, RECOVER TLC Workshop

Tonix Pharmaceuticals (NASDAQ: TNXP) CEO Seth Lederman, MD, participated at a recent event hosted by the Foundation for the National Institutes of Health (“FNIH”) and the National Institute of Allergy and Infectious Diseases (“NIAID”). According to an announcement from the fully integrated biopharmaceutical company, Lederman was a panel member at the “RECOVER Treating Long COVID – Navigating the Pathway Forward” workshop, which was held last week in Bethesda, Maryland. During the panel, experts discussed clinical trial endpoints that could provide meaningful data to support regulatory approval of potential Long COVID therapeutics. “We were honored to be invited to participate in the Long…

MondaySep 30, 2024 10:29 am

NetworkNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K

NanoViricides (NYSE American: NNVC), a development-stage company that is creating special purpose nanomaterials for antiviral therapy, filed its Annual Report on Form 10-K for the fiscal year ended June 30, 2024, on September 27, 2024. The company reported cash and cash equivalents of $4.97 million, approximately $7.5 million in Net Property and Equipment (“P&E”) assets (after depreciation), and total current liabilities of approximately $1.36 million as of June 30, 2024. During fiscal 2024, the company utilized net cash of approximately $6.31 million for operating activities, including certain expenditures for Phase 1a/1b clinical trial of NV-387 and drug manufacturing costs for…

FridaySep 27, 2024 3:33 pm

NetworkNewsBreaks – Key Trump Media & Technology Group Corp. (NASDAQ: DJT) Investor Unloads 11M Shares

United Atlantic Ventures LLC (“UAV”), a key investor in Trump Media & Technology Group (NASDAQ: DJT), significantly reduced its stake by selling nearly 11 million shares, leaving it with a mere 100 shares. This move came after a federal judge’s approval and the end of a lock-up period that initially restricted insiders from selling their shares. UAV, co-founded by Andrew Litinsky and Wes Moss, who played a pivotal role in conceptualizing a social media venture with Donald Trump, found itself embroiled in legal battles with Trump Media concerning their shareholdings. Despite these disputes and the fluctuating fortunes of Trump Media’s…

FridaySep 27, 2024 3:30 pm

NetworkNewsBreaks – Renforth Resources Inc. (CSE: RFR) (OTCQB: RFHRF) (FSE: 9RR) ‘Delivering on Multiple Fronts’ with Completed and Ongoing Exploration Efforts

Renforth Resources (CSE: RFR) (OTCQB: RFHRF) (FSE: 9RR), a Canada-based company engaged in the acquisition, exploration and development of mineral properties, provided an update on its summer exploration activities. “I am pleased to update fellow shareholders on our completed and ongoing exploration efforts, which touch almost all our wholly owned mineral assets. Our team continues to develop our understanding of our Beaupr copper discovery, testing its size on surface under cover, and we have commenced testing mineralized material from our Victoria polymetallic system for suitability for pre-concentration in a processing flow sheet, funded by the government of Quebec. We are…

FridaySep 27, 2024 3:20 pm

NetworkNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, announced Friday that it had received approval from an independent review board for its planned human pilot study #3. The approval signals that the company can begin the study, which aims to investigate the first ever DehydraTECH-processed version of tirzepatide, a dual action glucagon-like peptide (“GLP-1”) + glucose-dependent insulinotropic peptide (“GIP”), in an oral dose format. Tirzepatide is approved for use in the U.S. under the Eli Lilly(TM)-owned Zepbound(R) and Mounjaro(R) brands. Lexaria plans to begin subject enrollment shortly, with the company expecting to make an announcement as…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks